CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis

(2017) Tiancheng Zhao et al.   PLoS One

Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers

(2016) Jung Ho Kim et al.   BRITISH JOURNAL OF CANCER

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

(2016) Yayi He et al.   CANCER SCIENCE

Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma

(2016) Ching-Yao Yang et al.   EUROPEAN JOURNAL OF CANCER

Tumour CD274 (PD-L1) expression and T cells in colorectal cancer

(2016) Yohei Masugi et al.   GUT

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer

(2016) John R. Webb et al.   GYNECOLOGIC ONCOLOGY

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

Clinicopathologic profile, immunophenotype and genotype of CD274 (PD-L1)-positive colorectal carcinomas

(2016) Shingo Inaguma et al.   MODERN PATHOLOGY

Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

(2016) Xue Li et al.   Targeted Oncology

Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer

(2016) Dong-Qiang Zeng et al.   Oncotarget

PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

(2016) Hye Ryun Kim et al.   Scientific Reports

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy

(2015) Yanping Xiao et al.   Cancer Discovery

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

CD25 Identifies a Subset of CD4+FoxP3- TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer

(2014) R. J. deLeeuw et al.   Cancer Immunology Research

Chemotherapy of MMR-deficient colorectal cancer

(2013) N. Devaud et al.   Familial Cancer

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients

(2011) Reinhart Speeckaert et al.   EUROPEAN JOURNAL OF CANCER

Indoleamine 2,3-Dioxygenase

(2010) Hatem Soliman et al.   CANCER JOURNAL

Mismatch repair deficient colorectal cancer in the era of personalized treatment

(2010) Madeleine Hewish et al.   Nature Reviews Clinical Oncology

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT